Azabicycle MGL Modulators for ASD Social Interaction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no FDA-approved pharmacological treatments for the core symptoms of autism spectrum disorder (ASD) such as social communication, sensory hypersensitivity, and restricted, repetitive behaviors, highlighting a significant unmet need for new pharmacological interventions across the age spectrum.
Innovation Solution
Development of 3.1.0 and 4.1.0 azabicycle chemical entities with monoacylglycerol lipase (MGL) modulating properties for use in pharmaceutical compositions to treat ASD, potentially improving social interaction by modulating the endocannabinoid system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If CB1 agonists are used to treat autism spectrum disorder, then social interaction may be improved, but neurobehavioral side effects occur
Solution Approach 1:
The patent extracts and isolates the beneficial therapeutic effect from the harmful side effects by using MGL inhibitors to selectively increase 2-AG levels in specific brain regions, rather than using non-selective CB1 agonists that activate all CB1 receptors throughout the brain. This extraction approach allows obtaining social interaction benefits while eliminating the broad neurobehavioral side effects.
Solution Approach 2:
The patent applies local quality by utilizing the endogenous 2-AG system that naturally operates in specific brain regions with high CB1 density. By inhibiting MGL, 2-AG levels are increased locally where needed, providing region-specific modulation that improves social interaction without the widespread neurobehavioral effects of global CB1 agonist activation.
2Reliability
If MGL inhibitors are used to increase 2-AG levels, then endocannabinoid system modulation is achieved, but selective targeting of brain regions is required to minimize side effects
Solution Approach 1:
The patent uses MGL inhibitors as intermediary compounds that indirectly modulate the endocannabinoid system by preventing 2-AG degradation. This intermediary approach allows reliable endocannabinoid modulation through a different mechanism than direct CB1 agonism, achieving therapeutic effects while potentially reducing side effects through indirect action.
Solution Approach 2:
The patent employs the body's own endogenous 2-AG system to provide therapeutic effects. By inhibiting MGL, the natural 2-AG produced in the brain is preserved and enhanced, allowing the endocannabinoid system to self-regulate and provide benefits in a physiologically appropriate manner without requiring external agonists.
3Reliability
If pharmacological treatments are developed for core ASD symptoms, then treatment efficacy is improved, but FDA approval and clinical validation are required
Solution Approach 1:
The patent describes preclinical research and preclinical validation of MGL inhibitor compounds for ASD treatment. This preliminary action establishes the scientific basis and potential efficacy before entering the full FDA approval process, preparing the groundwork for future clinical development while acknowledging the regulatory pathway requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The azabicycle compounds enhance social interaction in subjects with ASD by increasing interest in social novelty, addressing core symptoms through MGL modulation without the full spectrum of neurobehavioral effects associated with CB1 agonists.
Implementation Method 1
Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2-AG into arachidonic acid and glycerol in the central nervous system
Implementation Method 2
3.1.0 and 4.1.0 azabicycle chemical entities having MGL modulating properties... The azabicycle compounds enhance social interaction in subjects with ASD by increasing interest in social novelty, addressing core symptoms through MGL modulation
Data Source
Figure 1A~1B
Figure 1C~1D
AI summary
The disclosure relates to certain uses and methods of use of 3.1.0 and 4.1.0 azabicycle compounds of Formula (I), wherein X, Y, R1, R2a, and R2b are defined herein, and pharmaceutical compositions containing them, in the treatment of autism spectrum disorder, including Asperger's syndrome.